New Velcade Indication Approved in Mantle Cell Lymphoma

Share this content:
Velcade (bortezomib) approved for the treatment of mantle cell lymphoma.
Velcade (bortezomib) approved for the treatment of mantle cell lymphoma.

Millennium: The Takeda Oncology Company announced that the Food and Drug Administration (FDA) has approved Velcade (bortezomib) for the treatment of mantle cell lymphoma (MCL) in previously untreated patients.

The approval is based on the results of an international, randomized, head-to-head Phase 3 study that showed that previously untreated patients receiving a Velcade-containing combination (VcR-CAP) experienced a 59% relative improvement in the study's primary endpoint of progression-free survival (PFS) compared to those who were administered the standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) regimen (median 25 vs. 14 months; HR 0.63; P<0.001) at a median follow up of 40 months. The complete response (CR) rate for patients receiving VcR-CAP vs. R-CHOP was 44% vs. 34%.

RELATED: Hematologic Cancers Drug Listings

Velcade is already indicated for multiple myeloma and in mantle cell lymphoma in patients who have received at least one prior therapy.

For more information call (866) 835-2233 or visit

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs